Targets › JAK1
30 programs from 25 companies in 271 trials: 118 Phase 2, 69 Phase 3, 61 Phase 1, 23 Phase 4; Immunology, Oncology, Other; next expected readout Nov 2026.
Non-membrane spanning protein tyrosine kinase that phosphorylates signal-transducing subunits of cytokine receptor complexes like IL2RB, IL10RA, IFNAR2, IL6ST, LIFR, OSMR and IL31RA. Functionally, is involved in the IFN-alpha/beta/gamma signal pathway. Mechanistically, in response to interferon-binding to IFNAR1-IFNAR2 heterodimer, phosphorylates and activates its binding partner IFNAR2, creating docking sites for…. (UniProt, P23458)
Open in Phaseline: the race on JAK1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Takeda | Tofacitinib Janus Kinase (JAK) inhibitor | JAK3, JAK1, JAK2, TYK2 | Phase 4 | Ulcerative Colitis; Rheumatoid Arthritis; Axial Spondyloarthritis; Oral Lichen Planus … | Jul 2027 |
| Eisai | Filgotinib Maleate Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase TYK2 inhibitor | JAK1, JAK2, TYK2, JAK3 | Phase 4 | Ulcerative Colitis | Nov 2027 |
| Incyte | Ruxolitinib Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor | JAK1, JAK2, JAK3, TYK2 | Phase 3 | NonSegmental Vitiligo; Hidradenitis Suppurativa; Atopic Dermatitis; Graft-versus-host Disease (GVHD) … | Nov 2026 |
| AbbVie | Upadacitinib Tyrosine-protein kinase TYK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor; Tyrosine-protein kinase JAK2 inhibitor | TYK2, JAK3, JAK2, JAK1 | Phase 3 | Atopic Dermatitis; Systemic Lupus Erythematosus; Ulcerative Colitis (UC); Crohn's Disease … | Nov 2026 |
| Incyte | povorcitinib JAK1 inhibitor | JAK1 | Phase 3 | Hidradenitis Suppurativa (HS); NonSegmental Vitiligo; Prurigo Nodularis; Moderate to Severe Asthma … | Nov 2026 |
| Jiangsu HengRui Medicine | SHR0302 JAK1 inhibitor | JAK1 | Phase 3 | Psoriatic Arthritis; Non-segmental Vitiligo | Dec 2026 |
| LEO Pharma | Delgocitinib Janus Kinase (JAK) inhibitor | JAK3, JAK1, JAK2, TYK2 | Phase 3 | Lichen Sclerosus; Palmoplantar Pustulosis; Central Centrifugal Cicatricial Alopecia; Vitiligo | Dec 2026 |
| Chia Tai Tianqing Pharmaceutical Group | TQ05105 Tablets (Rovadicitinib Tablets) Janus kinase 1 (JAK1), Janus kinase 2 (JAK2), and Rho-associated coiled-coil containing pr | JAK1, JAK2, ROCK2 | Phase 3 | Graft-versus-host Disease; Chronic Graft Versus Host Disease; Myelofibrosis | Dec 2026 |
| Pfizer | tofacitinib Janus Kinase (JAK) inhibitor | JAK3, JAK1, JAK2, TYK2 | Phase 3 | Ulcerative Colitis | Mar 2027 |
| Pfizer | Abrocitinib Tyrosine-protein kinase JAK1 inhibitor | JAK1 | Phase 3 | Eczema; Atopic Dermatitis; Post-COVID Condition; Diabetes Mellitus, Type 1 | May 2027 |
| Chengdu Zenitar Biomedical Technology | Flonoltinib Maleate JAK1/JAK2 inhibitor | JAK1, JAK2 | Phase 3 | MF; MF,PMF,PPV-MF,PET-MF; Polycythemia Vera (PV) | May 2027 |
| Sun Pharmaceutical Industries | Deuruxolitinib Phosphate (CTP-543) Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor | JAK1, JAK2, JAK3, TYK2 | Phase 3 | Alopecia Areata | May 2027 |
| Alfasigma | Filgotinib Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase TYK2 inhibitor | JAK1, JAK2, TYK2, JAK3 | Phase 3 | Polyarticular Course Juvenile Idiopathic Arthritis; Juvenile Idiopathic Arthritis (JIA); Ulcerative Colitis; Axial Spondyloarthritis … | Jun 2027 |
| Dizal Pharmaceuticals | Golidocitinib Tyrosine-protein kinase JAK1 inhibitor | JAK1 | Phase 3 | Peripheral T-cell Lymphoma; T-cell Lymphomas; Peripheral T Cell Lymphoma; Maintenance Treatment of Peripheral T-cell Lymphoma … | Nov 2027 |
| Priovant Therapeutics | Brepocitinib JAK1 inhibitor | JAK1 | Phase 3 | Uveitis, Posterior; Lichen Planopilaris; Cutaneous Sarcoidosis | Feb 2028 |
| Sun Pharma Japan | Deuruxolitinib JAK1 inhibitor | JAK1 | Phase 3 | Alopecia Areata | Feb 2028 |
| Eli Lilly | Baricitinib (LY3009104) Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor | JAK1, JAK2 | Phase 3 | Systemic Juvenile Idiopathic Arthritis; Areata Alopecia; Diabetes Mellitus, Type 1; Uveitis … | Mar 2028 |
| Suzhou Zelgen Biopharmaceuticals | Jaktinib Hydrochloride Tablet JAK inhibitor | JAK1, JAK2, JAK3 | Phase 3 | Atopic Dermatitis | – |
| Incyte | Itacitinib Tyrosine-protein kinase JAK1 inhibitor | JAK1 | Phase 2 | B-Cell Malignancies; Systemic Sclerosis; Diffuse Large B Cell Lymphoma; Acute Lymphoblastic Leukemia … | Nov 2026 |
| Institute of Hematology & Blood Diseases Hospital, China | Golidocitnib JAK1 inhibitor | JAK1 | Phase 2 | Lymphoma, T-Cell | Nov 2026 |
| GSK | Momelotinib Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Activin receptor type-1 inhibitor | JAK1, JAK2, ACVR1 | Phase 2 | Primary Myelofibrosis; Myelodysplastic Syndromes; VEXAS Syndome; Myeloid Leukemia … | Dec 2026 |
| M.D. Anderson Cancer Center | Ruxolitinib Phosphate Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor | JAK1, JAK2, JAK3, TYK2 | Phase 2 | Splenomegaly; AML; Chronic Lymphocytic Leukemia; T-cell Prolymphocytic Leukemia … | Jan 2027 |
| Fudan University | SHR-0302 JAK inhibitor | JAK1, JAK2, JAK3 | Phase 2 | Relapsed/Refractory Peripheral T Cell Lymphoma | Feb 2027 |
| City of Hope Medical Center | Ruxolitinib Phosphate Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor | JAK1, JAK2, JAK3, TYK2 | Phase 2 | Acute Lymphoblastic Leukemia; Follicular Helper T-Cell Lymphoma; Hematopoietic and Lymphatic System Neoplasm | Mar 2027 |
| Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Ivarmacitinib Selective JAK1 inhibitor | JAK1 | Phase 2 | Graft-Versus-Host Disease(GVHD) | May 2028 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | Emactinib Sulfate JAK1 inhibitor | JAK1 | Phase 2 | Head and Neck Cancer Squamous Cell Carcinoma | Aug 2028 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | Ivarmacitinib JAK inhibitor | JAK1, JAK2 | Phase 2 | Esophageal Squamous Cell Carcinoma | Dec 2028 |
| Shixiu Wu | JAK Inhibitors Janus kinase inhibitors | JAK1, JAK2, JAK3, TYK2 | Phase 2 | Immune Checkpoint Inhibitors (ICI)-Related Dermatitis | – |
| AbbVie | Tofacitinib Janus Kinase (JAK) inhibitor | JAK3, JAK1, JAK2, TYK2 | Phase 1 | Healthy Volunteers | Dec 2026 |
| First Affiliated Hospital of Zhejiang University | Gecacitinib (also known as Jaktinib) JAK inhibitor | JAK1, JAK2, JAK3 | Phase 1 | Acute Graft Versus Host Disease | Dec 2027 |
Atopic Dermatitis (9) Rheumatoid Arthritis (9) Myelofibrosis (8) Acute Lymphoblastic Leukemia (7) Ulcerative Colitis (6) Alopecia Areata (5) Rheumatoid Arthritis (RA (4) Vitiligo (4) NonSegmental Vitiligo (4) Hidradenitis Suppurativa (4) Primary Myelofibrosis (4) Chronic Graft Versus Host Disease (3)
small molecule (26), mixed (2), antibody (1)
Incyte (3) Pfizer (2) Second Affiliated Hospital, Zhejiang University, School of Medicine (2) AbbVie (2) First Affiliated Hospital of Zhejiang University (1) Chia Tai Tianqing Pharmaceutical Group (1) Sun Pharmaceutical Industries (1) Dizal Pharmaceuticals (1) Alfasigma (1) Takeda (1) Chengdu Zenitar Biomedical Technology (1) Eli Lilly (1) LEO Pharma (1) Priovant Therapeutics (1) Institute of Hematology & Blood Diseases Hospital, China (1) GSK (1) Eisai (1) Jiangsu HengRui Medicine (1) City of Hope Medical Center (1) Shixiu Wu (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.